BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Antibody Drug Conjugates

Kelun-Biotech's Fourth Indication for ADC sac-TMT Accepted for Priority Review in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophob...

May 22, 2025 | News

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

Fujifilm Validates Cancer-Targeting Potential of Peptide-Oligonucleotide Conjugates Using Proprietary Cyclic Peptide Library

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation ...

May 21, 2025 | News

Minghui Pharma Licenses B7-H3 ADC MHB088C to Qilu for Greater China in RMB 1.345 Billion Deal

Minghui Pharmaceutical , a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Phar...

May 12, 2025 | News

BioDlink Supports Junshi Biosciences in Achieving IND Approval for JS212, Its First Bispecific ADC

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company...

May 09, 2025 | News

Ajinomoto and RIBOMIC Advance Next-Gen Aptamer Therapeutics with Extended Half-Life Using AJICAP® Technology

Ajinomoto Co., Inc. has been conducting joint research* with RIBOMIC Inc. (President: Yoshikazu Nakamura, Headquarters: Minato-ku, Tokyo, hereinafter refer...

May 07, 2025 | News

PCI Pharma Services Acquires Ajinomoto Althea’s Altair to Build Global Powerhouse in Aseptic Filling and Advanced Drug Delivery

PCI Pharma Services ("PCI") is pleased to announce the launch of Ajinomoto Althea, the world's leading contract research and manufacturing organi...

May 05, 2025 | News

Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, a First-in-Class Dual-Payload CEACAM5 ADC

Innovent Biologics, a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment ...

April 30, 2025 | News

Keymed Biosciences Advances CDH17-Targeted ADC CM518D1 Into Phase I/II Trials for Solid Tumors in China

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) develop...

April 28, 2025 | News

Akeso’s Ivonescimab Outperforms Pembrolizumab in Phase III, Wins NMPA Approval for First-Line PD-L1-Positive NSCLC

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has re...

April 28, 2025 | News

Lotte Biologics Seals First ADC Manufacturing Deal to Launch Full-Scale US Production

Lotte Biologics has announced the signing of its first official contract manufacturing agreement at its newly expanded antibody-drug conjugate (ADC) produc...

April 25, 2025 | News

Sichuan Kelun-Biotech Secures FDA IND Clearance for First-in-Class ADC SKB518

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new dru...

April 22, 2025 | News

Nona Biosciences Partners with Atossa Therapeutics to Advance Next-Generation Antibody Therapies for Breast Cancer

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody ...

April 11, 2025 | News

Mabwell’s B7-H3-Targeting ADC 7MW3711 Enters Phase Ib/II Trial in China for Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) ha...

April 03, 2025 | News

Stay Connected